Stanley Erck, Novavax CEO (Andrew Harnik, AP Images)
April 30, 2021 07:26 AM EDT
People
Coronavirus

Stan­ley Er­ck bagged $48M in pay as he guid­ed No­vavax on a re­mark­able turn­around in the hunt for a Covid-19 vac­cine

Kyle Blankenship

Among pan­dem­ic suc­cess sto­ries, on­ly Mod­er­na ri­vals Mary­land-based No­vavax’s re­mark­able rise from the bow­els of ob­scu­ri­ty to vac­cine play­er. Dri­ving that change was CEO Stan­ley …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times